Annexon, Inc. (ANNX) Reports In-Line Q2 EPS

Go back to Annexon, Inc. (ANNX) Reports In-Line Q2 EPS

H.C. Wainwright Reiterates Buy Rating on Annexon Biosciences (ANNX)

August 13, 2024 6:20 AM EDT

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $30.00 price target on Annexon Biosciences (NASDAQ: ANNX).

The analyst comments "Valuation and Risks. Our price target of $30 is based on an equally weighted composite of: (a) $31.56/share, as a 30x multiple taxed and... More